每(mei)經AI快訊，據中山萊(lai)博(bo)瑞辰(chen)生物(wu)醫藥(yao)公(gong)(gong)眾(zhong)(zhong)號，2023年(nian)8月，中山萊(lai)博(bo)瑞辰(chen)生物(wu)醫藥(yao)有(you)限公(gong)(gong)司(si)宣布完(wan)成數千萬(wan)元A+輪融(rong)(rong)資(zi)(zi)。本(ben)輪融(rong)(rong)資(zi)(zi)由(you)國(guo)內知名投(tou)(tou)(tou)資(zi)(zi)機構珠(zhu)海(hai)和誠智(zhi)益資(zi)(zi)本(ben)管理(li)有(you)限公(gong)(gong)司(si)領投(tou)(tou)(tou)，中山創業投(tou)(tou)(tou)資(zi)(zi)有(you)限公(gong)(gong)司(si)、珠(zhu)海(hai)一(yi)豪投(tou)(tou)(tou)資(zi)(zi)有(you)限公(gong)(gong)司(si)、珠(zhu)海(hai)小眾(zhong)(zhong)匯海(hai)股權投(tou)(tou)(tou)資(zi)(zi)基金(jin)合伙企業跟投(tou)(tou)(tou)，百洋(yang)醫藥(yao)集團(tuan)繼(ji)A輪以旗(qi)下百洋(yang)眾(zhong)(zhong)信基金(jin)領投(tou)(tou)(tou)后，此(ci)次(ci)繼(ji)續跟投(tou)(tou)(tou)加持。本(ben)輪融(rong)(rong)資(zi)(zi)資(zi)(zi)金(jin)將用于(yu)加快推進骨(gu)與關節(jie)領域臨床階段和臨床前(qian)創新(xin)藥(yao)物(wu)的研發，加快團(tuan)隊(dui)建(jian)設、完(wan)善(shan)公(gong)(gong)司(si)架構等。（每(mei)日經濟新(xin)聞）